Retinoid X receptor Ligands with anti-type 2 diabetic activity

Ken Ichi Morishita, Hiroki Kakuta

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that plays an important role in regulating glucose metabolism. Agonists of PPARγ, such as thiazolidinediones, have anti-hyperglycemic activity, and are therefore used to treat type 2 diabetes. However, the functional activity of PPARγ is manifested by heterodimers of PPARγ with retinoid X receptors (RXRs). Since RXR/PPARγ heterodimers can be activated not only by PPARγ agonists, but also by RXR agonists, RXR agonists are also attractive candidates for treatment of type 2 diabetes. However, RXR full agonists have side effects, such as triglyceride elevation and hypothyroidism. Therefore, RXR partial agonists have been developed as new anti-type 2 diabetes agent candidates with reduced side effects. In addition, RXR antagonists also show therapeutic potency in type 2 diabetes patients. Here, we review RXR full agonists, RXR antagonists, and RXR modulators (partial agonists) with reported anti-diabetic effects, and we discuss their potential suitability as antidiabetic agents.

Original languageEnglish
Pages (from-to)696-707
Number of pages12
JournalCurrent Topics in Medicinal Chemistry
Volume17
Issue number6
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Retinoid X Receptors
PPAR gamma
Ligands
Type 2 Diabetes Mellitus
Thiazolidinediones
Hypothyroidism
Hypoglycemic Agents
Triglycerides
Transcription Factors

Keywords

  • Agonists
  • Antagonists
  • Diabetes
  • Glucose-lowering effects
  • Partial-agonists
  • Retinoid X receptors

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Retinoid X receptor Ligands with anti-type 2 diabetic activity. / Morishita, Ken Ichi; Kakuta, Hiroki.

In: Current Topics in Medicinal Chemistry, Vol. 17, No. 6, 01.03.2017, p. 696-707.

Research output: Contribution to journalReview article

@article{8c4da58be6fa4360910df2b9f8d91528,
title = "Retinoid X receptor Ligands with anti-type 2 diabetic activity",
abstract = "Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that plays an important role in regulating glucose metabolism. Agonists of PPARγ, such as thiazolidinediones, have anti-hyperglycemic activity, and are therefore used to treat type 2 diabetes. However, the functional activity of PPARγ is manifested by heterodimers of PPARγ with retinoid X receptors (RXRs). Since RXR/PPARγ heterodimers can be activated not only by PPARγ agonists, but also by RXR agonists, RXR agonists are also attractive candidates for treatment of type 2 diabetes. However, RXR full agonists have side effects, such as triglyceride elevation and hypothyroidism. Therefore, RXR partial agonists have been developed as new anti-type 2 diabetes agent candidates with reduced side effects. In addition, RXR antagonists also show therapeutic potency in type 2 diabetes patients. Here, we review RXR full agonists, RXR antagonists, and RXR modulators (partial agonists) with reported anti-diabetic effects, and we discuss their potential suitability as antidiabetic agents.",
keywords = "Agonists, Antagonists, Diabetes, Glucose-lowering effects, Partial-agonists, Retinoid X receptors",
author = "Morishita, {Ken Ichi} and Hiroki Kakuta",
year = "2017",
month = "3",
day = "1",
doi = "10.2174/1568026616666160617085545",
language = "English",
volume = "17",
pages = "696--707",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Retinoid X receptor Ligands with anti-type 2 diabetic activity

AU - Morishita, Ken Ichi

AU - Kakuta, Hiroki

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that plays an important role in regulating glucose metabolism. Agonists of PPARγ, such as thiazolidinediones, have anti-hyperglycemic activity, and are therefore used to treat type 2 diabetes. However, the functional activity of PPARγ is manifested by heterodimers of PPARγ with retinoid X receptors (RXRs). Since RXR/PPARγ heterodimers can be activated not only by PPARγ agonists, but also by RXR agonists, RXR agonists are also attractive candidates for treatment of type 2 diabetes. However, RXR full agonists have side effects, such as triglyceride elevation and hypothyroidism. Therefore, RXR partial agonists have been developed as new anti-type 2 diabetes agent candidates with reduced side effects. In addition, RXR antagonists also show therapeutic potency in type 2 diabetes patients. Here, we review RXR full agonists, RXR antagonists, and RXR modulators (partial agonists) with reported anti-diabetic effects, and we discuss their potential suitability as antidiabetic agents.

AB - Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that plays an important role in regulating glucose metabolism. Agonists of PPARγ, such as thiazolidinediones, have anti-hyperglycemic activity, and are therefore used to treat type 2 diabetes. However, the functional activity of PPARγ is manifested by heterodimers of PPARγ with retinoid X receptors (RXRs). Since RXR/PPARγ heterodimers can be activated not only by PPARγ agonists, but also by RXR agonists, RXR agonists are also attractive candidates for treatment of type 2 diabetes. However, RXR full agonists have side effects, such as triglyceride elevation and hypothyroidism. Therefore, RXR partial agonists have been developed as new anti-type 2 diabetes agent candidates with reduced side effects. In addition, RXR antagonists also show therapeutic potency in type 2 diabetes patients. Here, we review RXR full agonists, RXR antagonists, and RXR modulators (partial agonists) with reported anti-diabetic effects, and we discuss their potential suitability as antidiabetic agents.

KW - Agonists

KW - Antagonists

KW - Diabetes

KW - Glucose-lowering effects

KW - Partial-agonists

KW - Retinoid X receptors

UR - http://www.scopus.com/inward/record.url?scp=85011085629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011085629&partnerID=8YFLogxK

U2 - 10.2174/1568026616666160617085545

DO - 10.2174/1568026616666160617085545

M3 - Review article

VL - 17

SP - 696

EP - 707

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 6

ER -